Iovance Biotherapeutics Inc (IOVA) Stock Price, Quote & News

Company Profile

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an int...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 260 7120

Website: www.iovance.com

Address:

825 Industrial Road, Suite 100, San Carlos, United States

smolawoo Sep. 18 at 1:05 PM

$IOVA Inflows into IOVA by funds as they balance due to strong Q2 and strong guidance?

0 · Reply

Flyingkitty Sep. 18 at 12:53 PM

$IOVA Interesting... To all a great weekend... https://www.reddit.com/r/HotScienceNews/comments/1wjmflo/3yearold_boys_cancer_disappears_after_he_gets/

0 · Reply

DanSfera Sep. 18 at 12:46 PM

$IOVA for those who missed it; give us this day our daily bread and grateful to be aware of this gem https://youtube.com/live/zjtQyzjxoh0?feature=share

2 · Reply

Whiskeyunderthebed Sep. 18 at 12:45 PM

$IOVA Not so concerned about today- we did 24M shares yesterday and hit the 52 week high at $10.98- this is far from being the top.

0 · Reply

De12 Sep. 18 at 12:20 PM

$IOVA No insider buys from Rothbaum for over 1 year! Deal is on the Table!! Shorts Better Cover! Could Wake up to $30 on Monday!!

2 · Reply

DGANG3 Sep. 18 at 12:20 PM

$IOVA On our way to $15 where we belong pre-earnings and lung! Why? Because today we have a Platform, Manufacturing, an FDA approved drug, Revenue, Cash in the bank, a robust pipeline with great trials, and a sales force. Oh, a a chairman with experience. $20's by end of year!

1 · Reply

JM9190 Sep. 18 at 12:11 PM

$IOVA Which happens first - Profitability, 70% margins, 2L NSCLC FDA approval, or <5% short interest?

5 · Reply

De12 Sep. 18 at 12:06 PM

$IOVA Higher Revenue Guidance going to Drop on Monday!! Shorts Better Cover!! Bust that $11 on the way to $18!!

1 · Reply

beachsidefreddy Sep. 18 at 11:58 AM

$IOVA Oh, what a wicked web we weave, when first we practice to deceive! the option mm today!!!!!! they will get their $10

1 · Reply

OldGoldHawkeye Sep. 18 at 11:53 AM

$IOVA Amtagvi didn’t appear out of nowhere. It is NCI science that FDA already knew how to review. Rosenberg’s lab built TIL. NIH licensed it. Puri spent decades inside CBER on cell therapy after training in that same NCI group, then went to Iovance before the melanoma BLA. Theoret was on the OCE side of that review and later joined Iovance too. That is why the working relationship between FDA and IOVA looks unusually tight: same people, same platform, first commercial product. You can see it in the record. After the LUN-202 lymphodepletion death, FDA held the trial, then cleared a protocol change fast. Trial designs and Fast Tracks kept coming. 1/2

3 · Reply

Iovance Biotherapeutics put buyer realizes 64% same-day gains

2026-09-17T09:25:14.000Z - 1 day ago

Iovance Biotherapeutics price target raised to $15 from $13 at Barclays

Sep 15, 2026, 4:00 PM EDT - 2 days ago

Iovance Biotherapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference

Sep 10, 2026, 11:00 AM EDT - 7 days ago

Iovance Biotherapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference

Sep 4, 2026, 8:00 AM EDT - 14 days ago

Iovance Biotherapeutics to Present at Upcoming Conferences

2026-09-03T14:55:10.000Z - 14 days ago

Iovance Biotherapeutics put volume heavy and directionally bearish

2026-08-25T11:20:11.000Z - 24 days ago

Iovance Biotherapeutics price target raised to $10 from $7 at TD Cowen

Aug 21, 2026, 5:15 PM EDT - 27 days ago

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

2026-08-20T10:15:35.000Z - 4 weeks ago

Iovance Biotherapeutics price target raised to $7 from $4 at UBS

2026-08-18T11:06:16.000Z - 4 weeks ago

Iovance Biotherapeutics price target raised to $11 from $10 at Mizuho

2026-08-17T14:55:08.000Z - 4 weeks ago

Iovance Biotherapeutics put volume heavy and directionally bearish

2026-08-07T11:55:31.000Z - 6 weeks ago

Iovance Biotherapeutics price target raised to $6 from $4 at Baird

2026-08-07T10:21:31.000Z - 6 weeks ago

Iovance Biotherapeutics price target raised to $8 from $5 at Citizens

2026-08-07T09:40:45.000Z - 6 weeks ago

Iovance Biotherapeutics price target raised to $13 from $11 at Barclays

Aug 6, 2026, 8:30 AM EDT - 6 weeks ago

Iovance Biotherapeutics Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 6 weeks ago

Iovance Biotherapeutics Earnings release: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 6 weeks ago

Iovance Biotherapeutics Quarterly report: Q2 2026

2026-08-06T12:12:53.000Z - 6 weeks ago

Iovance Biotherapeutics backs FY26 revenue view $350M-370M, consensus $352M

2026-08-06T12:05:43.000Z - 6 weeks ago

Iovance Biotherapeutics reports Q2 EPS (11c), consensus (13c)

Aug 6, 2026, 7:01 AM EDT - 6 weeks ago

Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates

Jul 30, 2026, 8:00 AM EDT - 7 weeks ago

Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026

Jun 30, 2026, 7:00 AM EDT - 2 months ago

Iovance Biotherapeutics Slides: Corporate presentation

2026-06-18T20:35:12.000Z - 3 months ago

Iovance Biotherapeutics files automatic mixed securities shelf

Jun 10, 2026, 11:00 AM EDT - 3 months ago

Iovance Biotherapeutics Transcript: AGM 2026

Jun 4, 2026, 1:25 PM EDT - 3 months ago

Iovance Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2026

2026-06-03T20:45:39.000Z - 3 months ago

Iovance receives Australian approval of Amtagvi for advanced melanoma

Jun 3, 2026, 4:05 PM EDT - 3 months ago

Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

2026-06-01T13:15:52.000Z - 3 months ago

Iovance gets allowance to proceed from FDA for IOV-5001 IND application

Jun 1, 2026, 7:30 AM EDT - 3 months ago

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001

May 21, 2026, 8:05 AM EDT - 4 months ago

Iovance Biotherapeutics to Present at Upcoming Conference

2026-05-08T00:11:03.000Z - 4 months ago

Iovance Biotherapeutics price target lowered to $14 from $16 at Chardan

2026-05-07T13:16:25.000Z - 4 months ago

Iovance Biotherapeutics reports Q1 EPS (19c), consensus (15c)

2026-05-07T13:15:56.000Z - 4 months ago

Iovance Biotherapeutics sees Q2 revenue $86M-$88M, consensus $84.36M

2026-05-07T13:14:41.000Z - 4 months ago

Iovance Biotherapeutics sees FY26 revenue $350M-$370M, consensus $359.68M

May 7, 2026, 8:30 AM EDT - 4 months ago

Iovance Biotherapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 months ago

Iovance Biotherapeutics Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 4 months ago

Iovance Biotherapeutics Quarterly report: Q1 2026

May 7, 2026, 7:05 AM EDT - 4 months ago

Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Iovance Biotherapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Iovance Biotherapeutics Proxy statement: Proxy filing

Apr 27, 2026, 8:01 AM EDT - 4 months ago

Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026

Apr 17, 2026, 8:00 AM EDT - 5 months ago

Iovance Biotherapeutics Proxy statement: Proxy filing

Mar 11, 2026, 9:30 AM EDT - 6 months ago

Iovance Biotherapeutics Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 2, 2026, 9:50 AM EST - 6 months ago

Iovance Biotherapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 8:30 AM EST - 6 months ago

Iovance Biotherapeutics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 8:30 AM EST - 6 months ago

Iovance Biotherapeutics Annual report: Q4 2025

Feb 24, 2026, 8:30 AM EST - 6 months ago

Iovance Biotherapeutics Earnings release: Q4 2025

Feb 24, 2026, 7:00 AM EST - 6 months ago

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

Feb 24, 2026, 7:00 AM EST - 6 months ago

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

Feb 24, 2026, 7:00 AM EST - 6 months ago

Iovance Biotherapeutics Slides: Corporate presentation

Feb 11, 2026, 4:05 PM EST - 7 months ago

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

Feb 5, 2026, 5:15 PM EST - 7 months ago

Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

Jan 9, 2026, 7:00 AM EST - 8 months ago

Iovance Biotherapeutics Slides: Corporate presentation

Nov 6, 2025, 8:30 AM EST - 10 months ago

Iovance Biotherapeutics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Iovance Biotherapeutics Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Iovance Biotherapeutics Earnings release: Q3 2025

Sep 9, 2025, 11:00 AM EDT - 1 year ago

Iovance Biotherapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 8:00 AM EDT - 1 year ago

Iovance Biotherapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 18, 2025, 4:15 PM EDT - 1 year ago

Iovance's Amtagvi® (lifileucel) Receives Health Canada Approval for Advanced Melanoma

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Iovance Biotherapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Iovance Biotherapeutics Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Iovance Biotherapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:01 PM EDT - 1 year ago

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025

Jul 23, 2025, 12:08 PM EDT - 1 year ago

Here's why Iova stock surged 32% today and why the rally might not be over

Jul 15, 2025, 7:30 AM EDT - 1 year ago

Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer

Jul 14, 2025, 9:04 AM EDT - 1 year ago

IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV

Jul 14, 2025, 7:30 AM EDT - 1 year ago

Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma

Jul 10, 2025, 4:01 PM EDT - 1 year ago

Iovance Biotherapeutics Appoints Marc R. Theoret, M.D.

Jul 10, 2025, 8:18 AM EDT - 1 year ago

IOVA COURT NOTICE: Iovance Biotherapeutics Investors may have been Affected by Fraud – Contact BFA Law by the July 14 Legal Deadline (NASDAQ:IOVA)

Jun 28, 2025, 7:46 AM EDT - 1 year ago

IOVA INVESTOR DEADLINE: Iovance Biotherapeutics Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 20, 2025, 9:07 AM EDT - 1 year ago

IOVA COURT REMINDER: Iovance Biotherapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

Jun 18, 2025, 8:38 AM EDT - 1 year ago

IOVA NOTICE: Did Iovance Biotherapeutics, Inc. Mislead Investors? Contact BFA Law by July 14 Court Deadline if You Suffered Losses (NASDAQ:IOVA)

Jun 16, 2025, 8:17 AM EDT - 1 year ago

IOVA SHAREHOLDER REPORT: Iovance Biotherapeutics, Inc. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 14 Court Deadline (NASDAQ:IOVA)

smolawoo Sep. 18 at 1:05 PM

$IOVA Inflows into IOVA by funds as they balance due to strong Q2 and strong guidance?

0 · Reply

Flyingkitty Sep. 18 at 12:53 PM

$IOVA Interesting... To all a great weekend... https://www.reddit.com/r/HotScienceNews/comments/1wjmflo/3yearold_boys_cancer_disappears_after_he_gets/

0 · Reply

DanSfera Sep. 18 at 12:46 PM

$IOVA for those who missed it; give us this day our daily bread and grateful to be aware of this gem https://youtube.com/live/zjtQyzjxoh0?feature=share

2 · Reply

Whiskeyunderthebed Sep. 18 at 12:45 PM

$IOVA Not so concerned about today- we did 24M shares yesterday and hit the 52 week high at $10.98- this is far from being the top.

0 · Reply

De12 Sep. 18 at 12:20 PM

$IOVA No insider buys from Rothbaum for over 1 year! Deal is on the Table!! Shorts Better Cover! Could Wake up to $30 on Monday!!

2 · Reply

DGANG3 Sep. 18 at 12:20 PM

1 · Reply

JM9190 Sep. 18 at 12:11 PM

$IOVA Which happens first - Profitability, 70% margins, 2L NSCLC FDA approval, or <5% short interest?

5 · Reply

De12 Sep. 18 at 12:06 PM

$IOVA Higher Revenue Guidance going to Drop on Monday!! Shorts Better Cover!! Bust that $11 on the way to $18!!

1 · Reply

beachsidefreddy Sep. 18 at 11:58 AM

$IOVA Oh, what a wicked web we weave, when first we practice to deceive! the option mm today!!!!!! they will get their $10

1 · Reply

OldGoldHawkeye Sep. 18 at 11:53 AM

3 · Reply

sck2 Sep. 18 at 11:51 AM

$IOVA If you force me to choose one of IOVA vs. CAPR today, for the next 12 months and for the longer term, I would choose IOVA. Not because CAPR can't produce the larger percentage move. CAPR absolutely can. In fact, CAPR probably has the more explosive binary upside if the FDA ultimately approves Deramiocel. But if I'm putting my own hypothetical money into one of these two and I want the best combination of probability, underlying business, balance sheet, catalysts and long-term value creation, I'm taking IOVA. And after digging through the newest information, I feel more strongly about that distinction than I did before. GLTYA trading investing. ✅💪IOVA💎

0 · Reply

YungBullHOLLA Sep. 18 at 11:50 AM

$IOVA found on X Fuck the shirts yall

0 · Reply

ceemo0128 Sep. 18 at 11:39 AM

$IOVA There was a ton of open interest on the $10 calls expiring today. That made me think that MM would push us down to 9.99 to kill those. The number was cut in half over the day yesterday, making me feel a little better about a continued move up today! Let's get it! GLTA!

0 · Reply

sck2 Sep. 18 at 11:34 AM

$IOVA we do expect a little consolidation here with a move up to $15 in-play ... if you have any dry powder use it ... *not a financial advice* ... 😊😜🤑💎

0 · Reply

YungBullHOLLA Sep. 18 at 11:21 AM

$IOVA the ATC network is already set The second that NSCLC indication is approved It’s a plug and play revenue accelerant

0 · Reply

Xanderzzzzzzz Sep. 18 at 11:11 AM

$IOVA …

0 · Reply

Xanderzzzzzzz Sep. 18 at 11:09 AM

$IOVA

0 · Reply

Magnificient Sep. 18 at 11:05 AM

$IOVA today Triple witching

0 · Reply

OldGoldHawkeye Sep. 18 at 10:57 AM

$IOVA

0 · Reply

OldGoldHawkeye Sep. 18 at 10:53 AM

$IOVA

0 · Reply

moegomma Sep. 18 at 10:42 AM

$IOVA Extremely

0 · Reply

sck2 Sep. 18 at 10:32 AM

$IOVA Zero in score indicates that our system is expecting high volatility and risk for the following trading day. Given the latest developments, we cannot determine the next direction as it may go both ways. Next trading day forecast Predicted Fair Opening Price September 18, 2026 $10.33 3.09% vs last close

0 · Reply

Market Cap	4.47B
Revenue (ttm)	263.50M
Net Income (ttm)	-390.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-148.38%
Debt to Equity Ratio	0.00

Volume	24,195,699
Avg Vol	17,078,391
Day's Range	N/A - N/A
Shares Out	452.97M
Stochastic %K	67%
Beta	0.83
Analysts	Strong Sell
Price Target	$9.90